Explore

Trendline Trendline
Eli Lilly Acquires Engage Bio to Enhance Genetic Medicines Portfolio

Eli Lilly Acquires Engage Bio to Enhance Genetic Medicines Portfolio

Eli Lilly Acquires Engage Bio to Enhance Genetic Medicines Portfolio
Trendline Trendline
Eli Lilly Acquires Engage Bio for $202 Million to Enhance Genetic Medicines Portfolio

Eli Lilly Acquires Engage Bio for $202 Million to Enhance Genetic Medicines Portfolio

Eli Lilly Acquires Engage Bio for $202 Million to Enhance Genetic Medicines Portfolio
Trendline Trendline
Regeneron and Parabilis Collaborate on $2.3 Billion Antibody-Peptide Conjugate Development

Regeneron and Parabilis Collaborate on $2.3 Billion Antibody-Peptide Conjugate Development

Regeneron and Parabilis Collaborate on $2.3 Billion Antibody-Peptide Conjugate Development
Trendline Trendline
BioMarin Faces Setback with Phase 3 Trial Failure in Rare Disease Treatment

BioMarin Faces Setback with Phase 3 Trial Failure in Rare Disease Treatment

BioMarin Faces Setback with Phase 3 Trial Failure in Rare Disease Treatment
Trendline Trendline
Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis

Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis

Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis
Trendline Trendline
Balt Expands Irvine Operations, Strengthening U.S. Growth Strategy

Balt Expands Irvine Operations, Strengthening U.S. Growth Strategy

Balt Expands Irvine Operations, Strengthening U.S. Growth Strategy
Trendline Trendline
Akari Therapeutics Reports Increased Net Loss in Q1 2026

Akari Therapeutics Reports Increased Net Loss in Q1 2026

Akari Therapeutics Reports Increased Net Loss in Q1 2026
Trendline Trendline
Elon Musk Loses Lawsuit Against OpenAI and Sam Altman

Elon Musk Loses Lawsuit Against OpenAI and Sam Altman

Elon Musk Loses Lawsuit Against OpenAI and Sam Altman
Trendline Trendline
Parabilis Biotech Files for IPO to Fund Cancer Drug Trials

Parabilis Biotech Files for IPO to Fund Cancer Drug Trials

Parabilis Biotech Files for IPO to Fund Cancer Drug Trials
Trendline Trendline
Novo Nordisk and KBP Bio Dispute Heads to Arbitration

Novo Nordisk and KBP Bio Dispute Heads to Arbitration

Novo Nordisk and KBP Bio Dispute Heads to Arbitration
Reuters Reuters
Regeneron drops after skin cancer treatment fails late-stage trial

Regeneron drops after skin cancer treatment fails late-stage trial

By Christy Santhosh May 18 (Reuters) - Regeneron's shares fell 12% in morning trade on Monday after the company's experimental treatment missed the main goal in a late-stage trial for patients with a type of skin cancer.
Trendline Trendline
Novastra Therapeutics Appoints New CFO to Propel Global Clinical Development

Novastra Therapeutics Appoints New CFO to Propel Global Clinical Development

Novastra Therapeutics Appoints New CFO to Propel Global Clinical Development